Inactive Instrument

Mateon Therapeutics Inc Stock price OTC Bulletin Board

Equities

Biotechnology & Medical Research

End-of-day quote OTC Bulletin Board
- USD 0.00% Intraday chart for Mateon Therapeutics Inc
Sales 2021 - Sales 2022 - Capitalization 17.6M
Net income 2021 -9M Net income 2022 5M EV / Sales 2021 -
Net Debt 2021 8.42M Net Debt 2022 11.02M EV / Sales 2022 -
P/E ratio 2021
-5.42 x
P/E ratio 2022
4.5 x
Employees -
Yield 2021 *
-
Yield 2022
-
Free-Float 45.1%
More Fundamentals * Assessed data
Oncotelic Therapeutics, Inc. Announces Linkage of Cancer and Lupus in Gliomas Patients CI
Earnings Flash (OTLC) ONCOTELIC THERAPEUTICS Posts Q3 Revenue $70,000 MT
Oncotelic Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Oncotelic Therapeutics, Inc. announces tranche update CI
Oncotelic Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
Oncotelic Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Oncotelic Launches PDAO SEC chatbot CI
Oncotelic Therapeutics and Vectara Announce Strategic Partnership to Transform Pharmaceutical Research with Large Language Model Technology CI
Oncotelic Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022 CI
Oncotelic Therapeutics, Inc. Auditor Raises 'Going Concern' Doubt CI
Oncotelic Therapeutics, Inc Announces The Publication of High Intra-Tumor Transforming Growth Factor ?2 Level as A Predictor of Poor Treatment Outcomes in Pediatric Cancer of the Brainstem CI
Oncotelic Therapeutics, Inc. announced that it expects to receive $5 million in funding CI
Oncotelic Therapeutics, Inc. Announces Executive Changes CI
Oncotelic Announces Initiation of Clinical Study in Non-Small Lung Cell Cancer CI
Oncotelic Therapeutics, Inc. Initiates Clinical Trials Evaluating OT-101 against Metastatic Pancreatic Cancer CI
More news
Managers TitleAgeSince
Chief Executive Officer 59 19-04-21
Director of Finance/CFO 57 19-06-30
Chief Tech/Sci/R&D Officer 75 20-01-05
Members of the board TitleAgeSince
Director/Board Member 59 20-05-10
Chief Tech/Sci/R&D Officer 71 20-05-10
Chief Executive Officer 59 19-04-21
More insiders
Oncotelic Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing drugs for the treatment of orphan oncology indications, developing antisense and small molecule injectable drugs for the treatment of cancer. The Company's pipeline includes OT-101, CA4P and Oxi4503. OT-101 is antisense against TGF-2 for the treatment of solid tumors with focus on brain cancer in adults and diffuse intrinsic pontine glioma (DIPG) in children. OT-101 is antisense against TGF-2 for the treatment of various viruses, including the SARS and the COVID-19, on its own and in conjunction with other compounds. CA4P is a vascular disrupting agent (VDA) in combination with Ipilimumab for the treatment of solid tumors with focus on melanoma in adult and pediatric melanoma. Oxi4503 is VDA for the treatment of liquid tumors with a focus on childhood leukemia.
More about the company
  1. Stock
  2. Equities
  3. Stock Oncotelic Therapeutics, Inc.
  4. Stock Mateon Therapeutics Inc - OTC Bulletin Board